Is immunoglobulin A nephropathy different in different ethnic populations?
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Immunoglobulin A nephropathy (IgAN) is one of the commonest global patterns of primary glomerulonephritis and remains a leading cause of chronic kidney disease and end‐stage renal disease. The sole diagnostic criterion of IgAN remains the presence of dominant mesangial immunoglobulin A deposits on kidney biopsy. Beyond this defining feature, there is significant heterogeneity in the epidemiology, clinical presentation, renal progression and long‐term outcomes of IgAN in different ethnic populations. Mirroring this heterogeneity in clinical phenotypes, there is also marked ethnic variation in the extent of histopathological lesions observed on kidney biopsy, which may partly explain the well‐documented differences in response to immunomodulatory agents reported in different regions of the world. In parallel, disparities have been identified in genetic association studies and key pathogenic pathways in different ethnic populations. Understanding the basis for these differences in IgAN has important implications for both clinical care and future research. In this review, we will examine the impact of ethnicity on the epidemiology, clinical presentation and outcomes, pathogenesis and genetic associations in IgAN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wyatt, R. J., & Julian, B. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1206793 · Cited by 1,222
Intensive supportive care plus immunosuppression in IgA nephropathy
Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415463 · Cited by 726
Cited by
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
Mathur, M., Barratt, J., Chacko, B., Chan, T. M., Kooienga, L., Oh, K.-H., Sahay, M., Suzuki, Y., Wong, M. G., Yarbrough, J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2305635 · Cited by 239
Self-citationSibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
Perkovic, V., Trimarchi, H., Tesar, V., Lafayette, R., Wong, M. G., Barratt, J., Suzuki, Y., Liew, A., Zhang, H., Carroll, K., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2512133 · Cited by 90
Self-citationThe expanding role of biomarkers in the management of IgA nephropathy
Jain, K., & Rizk, D. V. (2026) · Kidney International Supplements · doi:10.1016/j.kisu.2026.01.004 · Cited by 6
Individualised treatment effects of corticosteroids in IgA nephropathy
Hölscher, D. L., Schmitz, N. E. J., Niggemeier, L., Pilva, P., Strauch, M., Tesar, V., Barratt, J., Roberts, I. S. D., Coppo, R., Barisoni, L., et al. (2026) · eBioMedicine · doi:10.1016/j.ebiom.2026.106396 · Cited by 2
“35 All included biopsy cases were scored locally in accordance with the Oxford classification for IgAN, 20,36 missing cases were rescored centrally blinded to clinical and other pathological data.”
Self-citationUrinary IL-18 predicts progression of IgA nephropathy
Tang, Y., Tao, X., Huang, C., Teng, S., Lin, X., Tian, J., Liao, Y., Mei, J., & Ou, J. (2026) · BMC Nephrology · doi:10.1186/s12882-026-04965-3 · Cited by 2
Metadata
- Authors
- Yeo, S. C., Goh, S. M., & Barratt, J.
- Venue
- Nephrology
- Publisher
- Wiley
- Published
- 2019-05
- Volume
- 24
- Issue
- 9
- Pages
- 885-895
- ISSN
- 1320-5358 (ISSN-L)
- 1440-1797
- OpenAlex
- W2935962542
- Cited by
- 99
- References
- 2
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is immunoglobulin A nephropathy different in different ethnic populations? https://app.cochat.ai/papers/10.1111/nep.13592
- The paper
- Yeo, S. C., Goh, S. M., & Barratt, J. (2019). Is immunoglobulin A nephropathy different in different ethnic populations? Nephrology. https://doi.org/10.1111/nep.13592
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.